Multidisciplinary care coordination for cutaneous malignancies is shifting from centralized academic hubs to models that blend virtual tumor boards with secure mobile communication. According to Dr. Zeitouni and NP Schollenberger, these advancements allow community-based dermatologists and surgeons to access specialized oncological expertise without the geographic constraints of traditional hospital-based settings.
Virtual Tumor Boards and Decentralized Care
The transition toward virtual tumor boards gained momentum during the pandemic. Dr. Zeitouni notes that these platforms enable community practitioners to present complex cases to multidisciplinary teams, including medical and radiation oncologists, regardless of their physical location. For practices lacking formal tumor board infrastructure, Dr. Zeitouni suggests that establishing direct collegial relationships via phone or text remains a viable, effective alternative for coordinating treatment plans.
Pro Tip: If your practice lacks a formal tumor board, prioritize building a dedicated network of specialists. Establishing a reliable point of contact in medical oncology can significantly streamline the referral and decision-making process for complex cutaneous malignancies.
Mobile Health Technology in Specialty Referrals
At Johns Hopkins, the approach to multidisciplinary coordination involves both weekly tumor boards and new mobile technology. NP Schollenberger reports that her team is piloting a HIPAA-secure mobile application, developed by 1104 Health, to bridge the gap between community providers and academic specialists. This tool allows for direct, patient-level communication, ensuring that patients can often receive treatment locally while still benefiting from the oversight of cutaneous malignancy experts at an academic center.
Biomarkers and Risk Stratification in CSCC
Clinical management of Cutaneous Squamous Cell Carcinoma (CSCC) is increasingly guided by molecular diagnostics. Dr. Zeitouni highlights two primary emerging tools:
- Gene Expression Profiling: This provides prognostic risk stratification, categorizing patients into low, intermediate, or high-risk groups for metastasis at three years. This data allows clinicians to tailor the intensity of surveillance and imaging frequency.
- Circulating Tumor DNA (ctDNA) Liquid Biopsy: While already established for melanoma and Merkel cell carcinoma, this tool is now being applied to CSCC. According to Dr. Zeitouni, these tumor-informed assays are being used to monitor treatment response and assist in ongoing disease surveillance.
Did you know? Liquid biopsies represent a minimally invasive way to track disease progression. By analyzing ctDNA, clinicians can potentially detect recurrence earlier than traditional imaging methods in select patients.
Frequently Asked Questions
How do virtual tumor boards improve patient outcomes?
They provide community-based providers with immediate access to multidisciplinary expertise, ensuring that treatment plans are vetted by medical and radiation oncologists without requiring the patient to travel to an academic center.
What is the role of gene expression profiling in CSCC?
It helps quantify the risk of metastasis over a three-year period, allowing physicians to decide how aggressively they should monitor a patient and how often imaging scans are necessary.
Can community dermatologists use liquid biopsies?
Yes, circulating tumor DNA assays are increasingly used in clinical practice for treatment monitoring and surveillance, though they are often integrated into a broader multidisciplinary care plan.
Stay informed on the latest developments in dermatology and oncology. Subscribe to our clinical newsletter for weekly updates on multidisciplinary care trends and diagnostic innovations.
Worth a look